Gador

Gador is an established Argentine private pharmaceutical company founded in 1940, operating within the Healthcare and Pharmaceutical sectors. With a significant turnover exceeding USD100 million in Argentina, the company demonstrates substantial market presence. Gador employs between 500 - 1,000 professionals, underscoring its operational scale. Its product portfolio includes finished pharmaceutical goods and active principles, manufactured in plants approved by MERCOSUR, FDA, and EMEA authorities, ensuring high quality and compliance for international markets. The company's global reach extends to over 30 countries across five continents, highlighting its extensive distribution network and market penetration.

The company actively engages in strategic partnerships, notably in pharmaceutical distribution through Farmanet S.A. with major entities like Novartis and Boehringer Ingelheim. Gador is deeply invested in research and development, fostering long-standing scientific collaborations with institutions such as the University of Leiden and various Argentine universities. A key R&D focus is the development of a new molecule, Olpadronate (INN), for bone diseases like Paget's disease and other orphan conditions. Clinical trials have confirmed its high effectiveness and tolerance. Gador is recognized globally as one of only five companies researching bisphosphonates, holding a robust portfolio of patents and intellectual property rights. Meet Gador's team to understand the expertise driving these advancements.

Furthermore, Gador has a pioneering history in Chagas disease research, spanning over two decades. This dedication led to the development and production of the world's first commercial biotech diagnostic kit for Chagas disease, utilizing a unique blend of recombinant antigens from Trypanosoma cruzi. The company also represents licenses from prominentView more...